Telemonitoring in Inflammatory Bowel Disease: Findings from the TIGE-Rus Randomized Controlled Trial
Journal of Clinical Medicine · 20.06.2026 · 15 (12) · 4800
DOI: 10.3390/jcm15124800 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of Clinical Medicine, online erschienen am 20.06.2026. Verfasst von Dina A Akhmedzyanova und 11 weiteren Autor:innen. Beteiligte Einrichtung: Research and Practical Clinical Center for Diagnostics and Telemedicine Technologies of the Moscow Health Care Department, Moscow 127051, Russia. Die Arbeit nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Moscow Healthcare Department, Scientific rationale, concept, and methodology for patient management using artificial intelligence.
Abstract (Originalsprache)
Background
Telemedicine is increasingly used in inflammatory bowel disease (IBD), but its effects on quality of life (QoL) and psychological outcomes remain unclear.
Objectives
This study aimed to evaluate the impact of 6-month telemonitoring on QoL, disease activity, treatment adherence, psychological well-being, patient satisfaction, and healthcare utilization.
Methods
This randomized, open-label, single-center study conducted in Russia (July 2023–December 2024) included adults with ulcerative colitis or Crohn’s disease, who were assigned 1:1 to telemonitoring or standard care. The intervention involved monthly remote assessments and access to a web-based platform containing educational information, disease activity assessment, and a chat with a gastroenterologist. The primary outcome was health-related QoL (SIBDQ). Exploratory outcomes included general QoL (WHOQOL-26), psychological well-being (HADS), alexithymia (TAS-26), visceral sensitivity (VSI), treatment adherence (GMAS), patient satisfaction (PSQ-18), achievement of clinical remission, and healthcare utilization.
Results
Sixty-eight patients completed the study (32 intervention, 36 control). Telemonitoring was associated with lower anxiety levels (β = −1.76, p = 0.021), reduced visceral sensitivity (β = −5.08, p = 0.039), and higher medication adherence (β = 1.75, p = 0.008). No significant associations were observed for SIBDQ, WHOQOL-26 domains, depressive symptoms, alexithymia, achievement of clinical remission, or patient satisfaction with care (p > 0.05). Patients in the telemonitoring group also required fewer outpatient visits (p < 0.001), with no difference in hospitalizations. Within-group analysis demonstrated improvements in QoL, treatment adherence, visceral sensitivity, and disease activity in the telemonitoring group, but not in the controls.
Conclusions
Six-month telemonitoring in IBD was associated with lower anxiety, reduced visceral sensitivity, improved treatment adherence, and fewer outpatient visits. The health-related QoL assessed by the SIBDQ did not differ compared to standard care. No clear clinical disadvantage compared with standard care was detected during the study period.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Research and Practical Clinical Center for Diagnostics and Telemedicine Technologies of the Moscow Health Care Department, Moscow 127051, Russia.
- The First Sechenov Moscow State Medical University (Sechenov University), Moscow 119991, Russia.
ORCID-Profile: Dina A Akhmedzyanova, Yuliya F Shumskaya, Kristina V Charaya, Anton V Vladzymyrskyy, Ivan A Blokhin
Förderung
- Moscow Healthcare Department
- Scientific rationale, concept, and methodology for patient management using artificial intelligence
Zitieren
APA
Akhmedzyanova, D. A., Shumskaya, Y. F., Charaya, K. V., Vasilev, Y. A., Vladzymyrskyy, A. V., Alymova, Y. A., Blokhin, I. A., Reshetnikov, R. V., Kuprina, I. V., Taschyan, O. V., Yurazh, M. V., & Mnatsakanyan, M. G. (2026). Telemonitoring in Inflammatory Bowel Disease: Findings from the TIGE-Rus Randomized Controlled Trial. Journal of Clinical Medicine, 15(12), 4800. https://doi.org/10.3390/jcm15124800
Vancouver
Akhmedzyanova DA, Shumskaya YF, Charaya KV, Vasilev YA, Vladzymyrskyy AV, Alymova YA, et al. Telemonitoring in Inflammatory Bowel Disease: Findings from the TIGE-Rus Randomized Controlled Trial. Journal of Clinical Medicine. 2026;15(12):4800. doi:10.3390/jcm15124800
BibTeX
@article{Akhmedzyanova2026,
author = {Akhmedzyanova, Dina A and Shumskaya, Yuliya F and Charaya, Kristina V and Vasilev, Yuriy A and Vladzymyrskyy, Anton V and Alymova, Yulya A and Blokhin, Ivan A and Reshetnikov, Roman V and Kuprina, Irina V and Taschyan, Olga V and Yurazh, Marta V and Mnatsakanyan, Marina G},
title = {Telemonitoring in Inflammatory Bowel Disease: Findings from the TIGE-Rus Randomized Controlled Trial},
journal = {Journal of Clinical Medicine},
year = {2026},
volume = {15},
number = {12},
pages = {4800},
doi = {10.3390/jcm15124800}
}
EUVIMED